Loading...
Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile
INTRODUCTION: Daclatasvir and Asunaprevir (DCV/ASV) have recently been approved for the treatment of chronic hepatitis C virus infection. In association, they are more effective and safer than previous available treatments, but more expensive. It is unclear if paying for the additional costs is an e...
Na minha lista:
| Udgivet i: | PLoS One |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Public Library of Science
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4636244/ https://ncbi.nlm.nih.gov/pubmed/26544203 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0141660 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|